A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower participants blood sugar levels. Participants will get Rybelsus® as prescribed to them by their study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor. Participants will be asked to complete some questionnaires about their diabetes treatment. Participants will complete these during their normally scheduled visits with the study doctor.

Official Title
-----------------
A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Canada

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: Oral Semaglutide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) Diagnosed with type 2 diabetes mellitus The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study Male or female, age above or equal to 18 years at the time of signing informed consent Available HbA1c value less than or equal to 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit' (V1) if in line with local clinical practice Treatment naïve to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of less than or equal to 14 days Exclusion Criteria: Previous participation in this study. Participation is defined as having given informed consent in this study Treatment with any investigational drug within 30 days prior to enrolment into the study Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with type 2 diabetes<br>Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment. | Drug: Oral Semaglutide<br>* Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Glycated haemoglobin (HbA1c) | Percent (%)-points | From baseline (week 0) to End of Study visit (V3) (week 34-44) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relative change in body weight | Percent | From baseline (week 0) to End of Study visit (V3) (week 34-44) | 
| Absolute change in body weight | Kilogram (Kg) | From baseline (week 0) to End of Study visit (V3) (week 34-44) | 
| HbA1c <7% (Yes/No) | Percentage of patients achieving or not achieving the target value | End of Study visit (V3) (week 34-44) | 
| HbA1c reduction >=1%-points and body weight reduction of >=5% (Yes/No) | Percentage of patients achieving or not achieving the reduction | From baseline (week 0) to End of Study visit (V3) (week 34-44) | 
| HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No) | Percentage of patients achieving or not achieving the reduction | From baseline (week 0) to End of Study visit (V3) (week 34-44) | 
| Diabetes Treatment Satisfaction Questionnaire, change (DTSQc), relative treatment satisfaction | The change version (DTSQc) has the same 8 items as the status version but is reworded to direct the patients to rate their change in treatment satisfaction compared to before being treated with oral semaglutide. Each question is scored on a scale of -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change. | End of Study visit (V3) (week 34-44) | 
| Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction | The status version (DTSQs) provides a measure of how satisfied patients are with their current diabetes treatment. It consists of 8 questions, which are to be answered on a Likert scale from 0 to 6 (0 = very dissatisfied to 6 = very satisfied). Six questions are summed to produce a total Treatment Satisfaction score. The remaining two questions are concerning perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia, respectively. | From baseline (week 0) to End of Study visit (V3) (week 34-44) |